Although still a clinical-stage biopharma company, Madrigal Pharmaceuticals, Inc. made an all-out showing at the American Association for the Study of Liver Disease annual meeting to establish its position as the leader in the NASH race – from sponsoring the wi-fi at the meeting and emblazoning its logo on many attendees’ hotel key cards to introducing a new chief commercialization officer and launching physician awareness efforts.
Madrigal has a 14 March US Food and Drug Administration action date for resmetirom (MDGL-3196), its thyroid hormone receptor beta...
